Pre-earnings options volume in 23andMe is 1.3x normal with calls leading puts 11:1. Implied volatility suggests the market is anticipating a move near 27.8%, or 0c, after results are released. Median move over the past eight quarters is 7.1%.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ME:
- ME Earnings this Week: How Will it Perform?
- Petros Pharmaceuticals launches U.S. distribution of STENDRA
- 23andMe’s Lemonaid Health collabs with Petros Pharmaceuticals
- 23andMe to Report Q4 and Full Year FY2024 Financial Results
- 23andMe to Present Preliminary Efficacy and Biomarker Data for 23ME-00610 at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting